2016
DOI: 10.1016/j.obmed.2016.01.002
|View full text |Cite
|
Sign up to set email alerts
|

Medical management of obesity in Scandinavia 2016

Abstract: Background: Preventive efforts with improved diet and more exercise have at best decelerated increasing prevalence of overweight and obesity in Scandinavia, and the complications call for more effective treatments. This review is an overview of dietary supplements, medical devices (for oral use), and pharmacological treatments approved in Scandinavian countries. Interventions: One dietary fibre supplement, glucomannan, may produce a weight loss of 0.8 kg over 3 months, but a recent meta-analysis questioned eff… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
10
0
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 45 publications
0
10
0
1
Order By: Relevance
“…Актуализация цели, поведенческие модификации, создание мотивации и комфортной психологической обстановки -необходи-мые условия успешной реализации программ по сниже-нию избыточного веса [4,30,54,55].…”
Section: роль образа жизни и окружающей среды в патогенезе ожиренияunclassified
“…Актуализация цели, поведенческие модификации, создание мотивации и комфортной психологической обстановки -необходи-мые условия успешной реализации программ по сниже-нию избыточного веса [4,30,54,55].…”
Section: роль образа жизни и окружающей среды в патогенезе ожиренияunclassified
“…Lifestyle interventions, involving dietary modifications and increased physical activity are of high importance in avoiding obesity; however, a high proportion of the individuals loses interest shortly after they have started their new lifestyle and return to their original one; therefore, the results are rarely permanent ( Curioni and Lourenço, 2005 ). In the past century, many pharmacons have been approved to support weight loss; however, currently only three APIs and one combination product are available for this indication in the European Union (EU) ( Tonstad et al, 2016 ). Several medicines are no longer available on the market because of safety concerns.…”
Section: Introductionmentioning
confidence: 99%
“…Body Mass Index (BMI) has gradually increased over the past three decades, with 39% and 13% of adults being overweight (BMI ≥ 25) or obese (BMI ≥ 30) worldwide [1]. Furthermore, in Scandinavia, we see comparable or even higher prevalence numbers [2]. This represents a major public health concern because a high BMI, and especially obesity, increases the risk of noncommunicable diseases, such as cardiovascular disease, type 2 diabetes, high blood pressure, musculoskeletal complaints, mental health challenges (such as depression), and some cancers [3].…”
Section: Introductionmentioning
confidence: 99%